Millennium Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Millennium Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-249,259	Closed	-$2.65M	–	4836
2019 Q4	$2.65M	Sell	249,259 -544,949	-69%	-$5.41M	﹤0.01%	2426
2019 Q3	$8.27M	Sell	794,208 -119,968	-13%	-$1.57M	0.01%	1415
2019 Q2	$14M	Buy	914,176 +650,854	+247%	+$9.41M	0.02%	1021
2019 Q1	$3.38M	Sell	263,322 -41,854	-14%	-$473K	0.01%	2033
2018 Q4	$2.9M	Buy	305,176 +157,031	+106%	+$2.04M	﹤0.01%	1974
2018 Q3	$2.46M	Sell	148,145 -13,590	-8%	-$218K	﹤0.01%	2300
2018 Q2	$2.6M	Buy	161,735 +101,679	+169%	+$1.82M	﹤0.01%	2227
2018 Q1	$919K	Sell	60,056 -229,949	-79%	-$3.58M	﹤0.01%	2732
2017 Q4	$4.52M	Buy	290,005 +256,665	+770%	+$3.43M	0.01%	1789
2017 Q3	$370K	Sell	33,340 -309,206	-90%	-$2.91M	﹤0.01%	2973
2017 Q2	$3.15M	Sell	342,546 -85,677	-20%	-$714K	0.01%	1792
2017 Q1	$3.66M	Buy	428,223 +263,921	+161%	+$2.41M	0.01%	1638
2016 Q4	$1.76M	Buy	164,302 +113,761	+225%	+$1.38M	﹤0.01%	1947
2016 Q3	$547K	Sell	50,541 -47,142	-48%	-$383K	﹤0.01%	2561
2016 Q2	$661K	Sell	97,683 -110,427	-53%	-$697K	﹤0.01%	2354
2016 Q1	$970K	Sell	208,110 -90,973	-30%	-$444K	﹤0.01%	2195
2015 Q4	$1.89M	Buy	299,083 +109,603	+58%	+$889K	﹤0.01%	1965
2015 Q3	$1.67M	Sell	189,480 -159,500	-46%	-$1.67M	﹤0.01%	2030
2015 Q2	$4.11M	Buy	348,980 +15,568	+5%	+$216K	0.01%	1511
2015 Q1	$4.82M	Buy	333,412 +170,005	+104%	+$2.6M	0.01%	1428
2014 Q4	$2.79M	Buy	163,407 +40,905	+33%	+$590K	0.01%	1744
2014 Q3	$1.53M	Buy	122,502 +6,667	+6%	+$82.1K	﹤0.01%	2045
2014 Q2	$1.7M	Buy	115,835 +29,344	+34%	+$450K	﹤0.01%	1890
2014 Q1	$1.76M	Sell	86,491 -6,133	-7%	-$149K	0.01%	1873
2013 Q4	$1.81M	Buy	92,624 +85,824	+1,262%	+$2.29M	0.01%	1897
2013 Q3	$308K	Sell	6,800 -1,900	-22%	-$62K	﹤0.01%	2850
2013 Q2	$207K	Buy	+8,700	New	+$139K	﹤0.01%	2739

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Millennium Management's STML Position: Q1 2020 in Review

Millennium Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 249,259 shares — an estimated $2.65M sold.

Millennium Management first reported a position in STML in Q2 2013 and held it in 27 quarters. The position peaked at $14M in Q2 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

Millennium Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Millennium Management sold 249,259 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $2.65M.
Millennium Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 27 quarters.
Millennium Management's Stemline Therapeutics, Inc. position peaked at $14M in Q2 2019.
94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on Millennium Management's 13F filing for Q1 2020, filed 14 May 2020.